-
Public health labs oppose field WMD testing
Without national performance standards and field validation, Association of Public Health Laboratories says the risks of false positives and false negatives are too high
-
-
Chemical found to inhibit anthrax germination
Seven different chemicals do the trick, but only one works inside mammalian cells
-
-
Drexel researchers develop rapid cantilever biosensor
Technology has applications from E. coli and anthrax to prostate cancer
-
-
Argonne researchers corral E. coli
Unlike traditional centrifuging techniques, the new approach allows selective concentration of healthy cells
-
-
Intralytix seeks FDA approval of E. coli spray
Intended to control pathogens in food processing and medical setting, technique relies on microphages to immobilize bacteria
-
-
MedImmune accepts $15.6 billion buy-out offer
AstraZeneca outbids Merck and others to get its hands on the FluMist vaccine
-
-
TB victim receives TV
Facing a life of civil commitment, Russian-born Arizonan earns his creature comforts
-
-
General Dynamics Canada wins Canadian bio-sensor contract
After six years of succesful naval deployments, government will buy CAN$30 million worth of GDC’s VP Bio Sentry systems
-
-
Biotech industry set to break flu vaccine production record
Officials say industry will produce 132 million doses, with both Sanofi and MedImmune ramping up production capacity
-
-
FDA approves first bird flu vaccine
Government has been stockpiling Sanofi Pasteur’s vaccine for some time, but now it can be distributed without signed consent; concerns remain about efficacy
-
-
Digital angel buys Chemring's McMurdo
$7.5 million deal expected to pay dividends in 2009 when COSPAS-SARSAT equipment is replaced
-
-
NIH awards $23 million for six new influzena research centers
Federal government gets serious by expanding the Centers of Excellence for Influenza Research and Surveillance program
-
-
VaxGen tries to regroup
After HHS cancels its $877 million anthrax vaccine, company looks to merge or partner with others
-
-
Protein Sciences tests caterpillar-based flu vaccine
New approach to vaccine development relies on insect cells rather than bird eggs; method offers improved speed and safety
-
-
MedImmune to explore buy-out options
Board of directors reacts to heightened interest from Big Pharma and growing shareholder disatisfication
-
